Anecdotally, a report by Tian et al. described a partial response in a patient with progressing metastatic HER2+ BC who underwent treatment with trastuzumab-treated NK cells, which was consistent with an increased activation and expansion of NK cells mediated by trastuzumab in vitro (90). Here, ERBB2 is linked to breast cancer.